Management of cerebral metastases from malignant melanoma: Results of a combined, simultaneous treatment with fotemustine and irradiation

Journal of Neuro-Oncology

Volumn 43, Issue 2, 1999, Pages 173-178

  Ulrich, Jens ^a,b   Gademann, Gunther ^a   Gollnick, Harald ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Brain metastases; Chemotherapy; DTIC; Fotemustine; Malignant melanoma; Radiation therapy

Indexed keywords

DACARBAZINE; FOTEMUSTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MELANOMA; REMISSION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0032869551     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006280304912     Document Type: Article

References (28)

1. Stevens G, Firth I, Coates A: Cerebral metastases from malignant melanoma. Radiother Oncol 23: 185-191, 1992
2. Atkinson L: Melanoma of the central nervous system. Aust N Z J Surg 48: 14-16, 1978
3. Schadendorf D, Worm M, Czarnetzki B: Brain metastases of metastatic malignant melanoma: Response to DTIC and interferon-gamma. J Neuro Oncol 16: 77-79, 1993
4. Phuphanich S, Jacobs M, Spiers A: Response of recurrent brain metastases in malignant melanoma to 5-fluorouracil and interferon-α therapy. J Neuroimag 4: 114-116, 1994
5. Madajewicz S, West CR, Park HC, Ghoorah J, Avellanosa AM, Takita H, Karakousis C, Vincent R, Caracandas J, Jennings E: Phase II Study - Intra-arterial BCNU therapy for metastatic brain tumors. Cancer 47: 653-657, 1981
6. Avril MF, Bonneterre J, Cupissol D, Grob JJ, Kalis B, Fumoleau P, Kerbrat P, Israel L, Fargeot P, Lambert D: Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 28A: 1807-1811, 1992
7. Binder M, Winkler A, Dorffner R, Glebowski E, Wolff K, Pehamberger H: Fotemustine plus dacarbazine in advanced stage III malignant melanoma. Eur J Cancer 28A: 1814-1816, 1992
8. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer JJ, Bonneterre J, Kerbat P, Bonerandi JJ, Bugat R, Montcuquet P, Cupissol D, Lauvin R, Vilmer C, Prache C, Bizzari JP: (1990) Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66: 1873-1878, 1990
9. Khayat D, Avril MF, Gerad B, Bertrand P, Bizzari JP, Cour V: Fotemustine: an overview of its clinical activity in dissminated malignant melanoma. Melanoma Res 2: 147-151, 1992
10. Merimsky O, Inbar M, Gerad B, Chaitchik S: Fotemustine - an advance in the treatment of metastatic melanoma. Melanoma Res 2: 401-406, 1992
11. Schallreuter KU, Wenzel E, Brassow FW, Becker J, Breitbart EW, Teichmann W: Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chem Pharm 29: 85-87, 1991
12. Kleeberg UR, Engel E, Israels P, Bröcker EB, Tilgen W, Kennes C, Gerard B, Lejeune F, Glabbeke MV, Lentz MA: Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 5: 195-200, 1995
13. Brega K, Robinson WA, Winston K, Wittenberg W: Surgical treatment of brain metastases in malignant melanoma. Cancer 66: 2105-2110, 1990
14. Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS: Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma. Cancer 45: 679-683, 1980
15. Fedorscsak I, Sipos L, Horvath A, Kontra G, Bognar L, Osztie E: Multiple intracranial melanoma metastases treated with surgery and radiosurgery with long term control. J Neuro Oncol 16: 173-176, 1993
16. Lejeune FY, Lienard D, Sales F, Badr-El-Din H: Surgical management of distant melanoma metastases. Sem Surg Oncol 8: 381-391, 1992
17. Somaza S, Kondziolka D, Lunsford LD, Kirkwood JM, Flickinger JC: Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 79: 661-666, 1993
18. Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM: Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 53: 2550-2552, 1984
19. Retsas S, Gershuny AR: Central nervous system involvment in malignant melanoma. Cancer 61: 1926-1934, 1988
20. Ulrich J, Gademann G, Rosin C, Kühne KH, Gollnick H: Simultaneous chemotherapy and radiotherapy for cerebral metastases from malignant melanoma. Melanoma Res 7 Suppl 1: S 18 Abstracts
21. Bröcker EB, Bohndorf W, Kämpgen E, Trcka J, Messer P, Tilgen W, Engenhart K, Flentje M: Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma Res 6: 399-401, 1996
22. Hidalgo V, Dy C, Hidalgo OF, Calvo F: Simultaneous Radiotherapy and cis-Platinum for the treatment of brain metastases. Am J Clin Oncol 10: 205-209, 1987
23. Willner J, Bohndorf W: ZNS-Metastasen beim maligner Melanom. Strahlenther Onkol 171: 165-173, 1995
24. Buckner J: Surgery, radiation therapy, and chemotherapy for metastatic tumors to the brain. Curr Opin Oncol 4: 518-524, 1992
25. Engenhart R, Kimmig BN, Höver KH, Wowra B, Romahn J, Lorenz WJ, van Kaick G, Wannenmacher M: Long Term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation. Cancer 71: 1353-1361, 1993
26. Adler JR, Cox RS, Kaplan I, Martin DP: Stereotactic radiosurgical treatment of brain metastases. J Neurosurg 76: 444-449, 1992
27. Merimsky O, Reider-Grosswasser M, Inbar M, Kovner F, Chaitchik S: Cerebral metastatic melanoma: correlation between clinical and CT findings. Melanoma Res 2: 385-391, 1992
28. Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990